Effect of Id Vaccines on the Tumor Mass and Clinical Outcome
| UPN . | Immuno Adjuvant . | Serum M Protein (mg/dL) . | Serum κ/λ Ratio . | % BM Plasma Cells . | Immuno Fixation . | FFDP (mo) . | OS (mo) . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre . | Post . | Pre . | Post . | Pre . | Post . | Pre . | Post . | ||||
| 14 | GM-CSF | 196 | 299 | 1.2 | 1.6 | 1 | 1 | Pos | Pos | 17 | 32+ |
| 240 | GM-CSF | 1,359 | 1,528 | 1.8 | 1.8 | 1 | 1 | Pos | Pos | 31+ | 31+ |
| 453 | IL-2 | 1,734 | 1,755 | 0.8 | 0.6 | 1 | 3 | Pos | Pos | 36 | 39+ |
| 485 | IL-2 | 1,207 | 1,189 | 2.4 | 2 | ND | ND | Neg | Neg | 14 | 33 |
| 510 | GM-CSF | 167 | 311 | 1.4 | 1.6 | 1 | 1 | Pos | Pos | 32+ | 32+ |
| 522 | GM-CSF | 1,285 | 1,388 | 0.6 | 0.4 | 2 | 5 | Pos | Pos | 19 | 36+ |
| 535 | GM-CSF | 63 | 122 | 1.6 | 1.4 | 1 | 1 | Pos | Pos | 15 | 19+ |
| 637* | GM-CSF | 148 | 1,258 | 1.8 | 0.7 | 1 | 2 | Pos | Pos | 4* | 20 |
| 734 | GM-CSF | 1,563 | 1,486 | 14.9 | 10.3 | 5 | 5 | ND | ND | 17+ | 17+ |
| 743 | GM-CSF | 0† | 0.5† | 1.2 | 1.4 | 1 | 10 | Neg | Neg | 9 | 20+ |
| 749 | GM-CSF | 627 | 738 | 2.1 | 2 | 1 | 1 | Pos | Pos | 20+ | 20+ |
| 847 | GM-CSF | 1,632 | 1,412 | 4.4 | 3.3 | 2 | 2 | Pos | Pos | 11+ | 11+ |
| UPN . | Immuno Adjuvant . | Serum M Protein (mg/dL) . | Serum κ/λ Ratio . | % BM Plasma Cells . | Immuno Fixation . | FFDP (mo) . | OS (mo) . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre . | Post . | Pre . | Post . | Pre . | Post . | Pre . | Post . | ||||
| 14 | GM-CSF | 196 | 299 | 1.2 | 1.6 | 1 | 1 | Pos | Pos | 17 | 32+ |
| 240 | GM-CSF | 1,359 | 1,528 | 1.8 | 1.8 | 1 | 1 | Pos | Pos | 31+ | 31+ |
| 453 | IL-2 | 1,734 | 1,755 | 0.8 | 0.6 | 1 | 3 | Pos | Pos | 36 | 39+ |
| 485 | IL-2 | 1,207 | 1,189 | 2.4 | 2 | ND | ND | Neg | Neg | 14 | 33 |
| 510 | GM-CSF | 167 | 311 | 1.4 | 1.6 | 1 | 1 | Pos | Pos | 32+ | 32+ |
| 522 | GM-CSF | 1,285 | 1,388 | 0.6 | 0.4 | 2 | 5 | Pos | Pos | 19 | 36+ |
| 535 | GM-CSF | 63 | 122 | 1.6 | 1.4 | 1 | 1 | Pos | Pos | 15 | 19+ |
| 637* | GM-CSF | 148 | 1,258 | 1.8 | 0.7 | 1 | 2 | Pos | Pos | 4* | 20 |
| 734 | GM-CSF | 1,563 | 1,486 | 14.9 | 10.3 | 5 | 5 | ND | ND | 17+ | 17+ |
| 743 | GM-CSF | 0† | 0.5† | 1.2 | 1.4 | 1 | 10 | Neg | Neg | 9 | 20+ |
| 749 | GM-CSF | 627 | 738 | 2.1 | 2 | 1 | 1 | Pos | Pos | 20+ | 20+ |
| 847 | GM-CSF | 1,632 | 1,412 | 4.4 | 3.3 | 2 | 2 | Pos | Pos | 11+ | 11+ |
Abbreviations: Pre, prevaccine value; Post, postvaccine value; ND, not done; FFDP, freedom from disease progression (calculated from the first immunization to the date of first treatment after vaccination or last follow-up); OS, overall survival (calculated from the first immunization to the date of death or last follow-up).
Treatment was not completed by this patient owing to disease progression.
Light chain disease (values are expressed as grams per 24 hours).